Clin2
NCT06236880Possibly a fitRecruiting

Testing GM-2505 for Moderate to Severe Depression

Major Depressive Disorder

Part of Mental health clinical trials.

This trial tests a new oral medication, GM-2505, for people with moderate to severe major depressive disorder (MDD). The goal is to see if it is safe and well-tolerated, either as a stand-alone treatment or alongside a stable SSRI/SNRI antidepressant.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
124 people
Ages
18 years to 65 years
Study type
Interventional

Who can take part

  • You are between 18 and 65 years old.
  • You have been diagnosed with moderate to severe major depressive disorder (MDD) without psychotic features.
  • You are not currently taking an antidepressant (Part A) OR you are stable on an SSRI or SNRI antidepressant (Part B).
  • You have no personal or family history of bipolar disorder, schizophrenia, or psychosis.
  • You are not currently taking an MAO inhibitor or tricyclic antidepressant.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07772531Not yet recruiting· Phase 2
BMS-986511 for major depressive disorder

This study tests an investigational drug called BMS-986511 in adults with moderate to severe depression. The goal is to see if it can improve symptoms.

Phoenix, Arizona
NCT07196501Recruiting· Phase 3
Study of a new add-on treatment for depression maintenance

This trial tests a new medication (NBI-1065845) added to your current antidepressant to see if it helps maintain improvement in depression. It is for people whose depression hasn't fully responded to their current oral antidepressant.

Oceanside, California
NCT06963021Recruiting· Phase 3
Study of NBI-1065845 for depression that hasn't fully responded to treatment

This trial tests an investigational drug called NBI-1065845 added to your current antidepressant. It is for people with moderate to severe depression or persistent depressive disorder who have not improved enough with oral antidepressants alone.

Chino, California
NCT06966401Recruiting· Phase 3
Long-term safety study of a new depression treatment

This study tests a new oral medication (NBI-1065845) added to your current antidepressant to see if it's safe and tolerable over a long period for people with depression that hasn't fully responded to treatment.

Huntsville, Alabama
NCT06786624Recruiting· Phase 3
Testing a new drug for depression that hasn't fully responded to treatment

This trial tests a new medication called NBI-1065845 added to your current antidepressant for people with depression that hasn't fully responded to treatment. It aims to see if this combination can better improve your symptoms.

Little Rock, Arkansas
NCT06054321Recruiting
Depression medication study for adults 19 to 65

This study tests a new way of choosing antidepressants for people with major depression. It's designed for adults aged 19–65 who have moderate to severe depression and are either starting a new antidepressant or have been off psychiatric meds for at least a month.

Gwangju

Hear when a new Major Depressive Disorder trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.